Bortezomib therapeutic effect is associated with expression of FGFR3 in multiple myeloma cells

Min Guan, Lijun Zhu, George Somlo, Alison Hughes, Bingsen Zhou, Yun Yen

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The ectopically expressed and deregulated fibroblast growth factor receptor 3 (FGFR3) has been observed in ∼20% of multiple myeloma (MM) patients. In this study, we investigated whether the therapeutic effect of bortezomib is associated with FGFR3 expression. Materials and Methods: Cell proliferation and apoptosis assays were performed in minimal FGFR3 expressing U266 cells and compared to U266 cells overexpressing FGFR3 wild-type (T-U266), or Y373C (Y-U266) or K650E (K-U266) mutant FGFR3. Results: Our results suggested cell survival decreases in a dose-dependent manner. Interestingly, expression of FGFR3 protein was similarly dose dependent on bortezomib. It is confirmed the bortezomib-induced apoptotic death is correlated with FGFR3 expression. Furthermore, increased expression of p-STAT3, Mcl-1 and VEGF suggested that bortezomib resistance associated with Y373C mutation and wild-type FGFR3 may be partly mediated through p-STAT3 signaling. Conclusion: Our data indicates that Y373C mutation and wild-type FGFR3 may be associated with bortezomib-related treatment resistance in multiple myeloma.

Original languageEnglish
Pages (from-to)1-9
Number of pages9
JournalAnticancer Research
Volume29
Issue number1
Publication statusPublished - Jan 1 2009
Externally publishedYes

Fingerprint

Receptor, Fibroblast Growth Factor, Type 3
Therapeutic Uses
Multiple Myeloma
Bortezomib
Mutation
Vascular Endothelial Growth Factor A
Cell Survival
Cell Proliferation
Apoptosis

Keywords

  • Bortezomib
  • FGFR3
  • Fibroblast growth factor receptor 3
  • Multiple myeloma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Bortezomib therapeutic effect is associated with expression of FGFR3 in multiple myeloma cells. / Guan, Min; Zhu, Lijun; Somlo, George; Hughes, Alison; Zhou, Bingsen; Yen, Yun.

In: Anticancer Research, Vol. 29, No. 1, 01.01.2009, p. 1-9.

Research output: Contribution to journalArticle

Guan, M, Zhu, L, Somlo, G, Hughes, A, Zhou, B & Yen, Y 2009, 'Bortezomib therapeutic effect is associated with expression of FGFR3 in multiple myeloma cells', Anticancer Research, vol. 29, no. 1, pp. 1-9.
Guan, Min ; Zhu, Lijun ; Somlo, George ; Hughes, Alison ; Zhou, Bingsen ; Yen, Yun. / Bortezomib therapeutic effect is associated with expression of FGFR3 in multiple myeloma cells. In: Anticancer Research. 2009 ; Vol. 29, No. 1. pp. 1-9.
@article{a38ec6149e51485b8d590a90aa351be6,
title = "Bortezomib therapeutic effect is associated with expression of FGFR3 in multiple myeloma cells",
abstract = "The ectopically expressed and deregulated fibroblast growth factor receptor 3 (FGFR3) has been observed in ∼20{\%} of multiple myeloma (MM) patients. In this study, we investigated whether the therapeutic effect of bortezomib is associated with FGFR3 expression. Materials and Methods: Cell proliferation and apoptosis assays were performed in minimal FGFR3 expressing U266 cells and compared to U266 cells overexpressing FGFR3 wild-type (T-U266), or Y373C (Y-U266) or K650E (K-U266) mutant FGFR3. Results: Our results suggested cell survival decreases in a dose-dependent manner. Interestingly, expression of FGFR3 protein was similarly dose dependent on bortezomib. It is confirmed the bortezomib-induced apoptotic death is correlated with FGFR3 expression. Furthermore, increased expression of p-STAT3, Mcl-1 and VEGF suggested that bortezomib resistance associated with Y373C mutation and wild-type FGFR3 may be partly mediated through p-STAT3 signaling. Conclusion: Our data indicates that Y373C mutation and wild-type FGFR3 may be associated with bortezomib-related treatment resistance in multiple myeloma.",
keywords = "Bortezomib, FGFR3, Fibroblast growth factor receptor 3, Multiple myeloma",
author = "Min Guan and Lijun Zhu and George Somlo and Alison Hughes and Bingsen Zhou and Yun Yen",
year = "2009",
month = "1",
day = "1",
language = "English",
volume = "29",
pages = "1--9",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "1",

}

TY - JOUR

T1 - Bortezomib therapeutic effect is associated with expression of FGFR3 in multiple myeloma cells

AU - Guan, Min

AU - Zhu, Lijun

AU - Somlo, George

AU - Hughes, Alison

AU - Zhou, Bingsen

AU - Yen, Yun

PY - 2009/1/1

Y1 - 2009/1/1

N2 - The ectopically expressed and deregulated fibroblast growth factor receptor 3 (FGFR3) has been observed in ∼20% of multiple myeloma (MM) patients. In this study, we investigated whether the therapeutic effect of bortezomib is associated with FGFR3 expression. Materials and Methods: Cell proliferation and apoptosis assays were performed in minimal FGFR3 expressing U266 cells and compared to U266 cells overexpressing FGFR3 wild-type (T-U266), or Y373C (Y-U266) or K650E (K-U266) mutant FGFR3. Results: Our results suggested cell survival decreases in a dose-dependent manner. Interestingly, expression of FGFR3 protein was similarly dose dependent on bortezomib. It is confirmed the bortezomib-induced apoptotic death is correlated with FGFR3 expression. Furthermore, increased expression of p-STAT3, Mcl-1 and VEGF suggested that bortezomib resistance associated with Y373C mutation and wild-type FGFR3 may be partly mediated through p-STAT3 signaling. Conclusion: Our data indicates that Y373C mutation and wild-type FGFR3 may be associated with bortezomib-related treatment resistance in multiple myeloma.

AB - The ectopically expressed and deregulated fibroblast growth factor receptor 3 (FGFR3) has been observed in ∼20% of multiple myeloma (MM) patients. In this study, we investigated whether the therapeutic effect of bortezomib is associated with FGFR3 expression. Materials and Methods: Cell proliferation and apoptosis assays were performed in minimal FGFR3 expressing U266 cells and compared to U266 cells overexpressing FGFR3 wild-type (T-U266), or Y373C (Y-U266) or K650E (K-U266) mutant FGFR3. Results: Our results suggested cell survival decreases in a dose-dependent manner. Interestingly, expression of FGFR3 protein was similarly dose dependent on bortezomib. It is confirmed the bortezomib-induced apoptotic death is correlated with FGFR3 expression. Furthermore, increased expression of p-STAT3, Mcl-1 and VEGF suggested that bortezomib resistance associated with Y373C mutation and wild-type FGFR3 may be partly mediated through p-STAT3 signaling. Conclusion: Our data indicates that Y373C mutation and wild-type FGFR3 may be associated with bortezomib-related treatment resistance in multiple myeloma.

KW - Bortezomib

KW - FGFR3

KW - Fibroblast growth factor receptor 3

KW - Multiple myeloma

UR - http://www.scopus.com/inward/record.url?scp=61449131671&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61449131671&partnerID=8YFLogxK

M3 - Article

C2 - 19331127

AN - SCOPUS:61449131671

VL - 29

SP - 1

EP - 9

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 1

ER -